Association of ABO blood group type with cardiovascular events in COVID-19
- 15 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 51 (3), 584-586
- https://doi.org/10.1007/s11239-020-02364-5
Abstract
Cardiovascular complications have been reported in patients with COVID-19. We sought to examine the association of ABO blood group type with cardiovascular complications in COVID-19. We examined 409 individuals enrolled in the COVID-19 Registry to Assess Frequency, Management, and Outcomes of Arterial and Venous Thromboembolic Complications (CORONA-VTE) who had ABO blood group data available. Multiple logistic regression was used to assess the association of ABO blood group types with three primary outcomes: major adverse cardiovascular events (MACE), major arterial and venous thrombosis and all-cause mortality. 201, 121, 61 and 26 individuals had blood group O, A, B and AB, respectively. In multivariable analysis, blood group A was associated with a 2.5-fold higher odds of MACE than blood group O (OR 2.47[1.18–5.18]). There was an effect suggesting a 2-fold higher odds of major thrombotic events in blood group A vs. O that did not reach statistical significance (OR 2.15 [0.89–5.20]). No association between blood group type and all-cause mortality was found. Compared with the other blood group types, blood group A was associated with an increased odds of MACE(ORA/non−A 2.18[1.11–4.29]), while blood group O was associated with lower odds of MACE(ORO/non−O 0.50[0.26–0.97]). In conclusion, blood group A was associated with an increased odds of MACE, whereas blood group O was associated with a reduction in the odds of MACE in patients with COVID-19. These findings may inform risk stratification of COVID-19 patients for cardiovascular complications. Additional studies are needed to validate our findings.Keywords
Funding Information
- Janssen Research and Development
This publication has 6 references indexed in Scilit:
- Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19Journal of the American College of Cardiology, 2020
- Genomewide Association Study of Severe Covid-19 with Respiratory FailureThe New England Journal of Medicine, 2020
- Blood type and outcomes in patients with COVID-19Annals of Hematology, 2020
- Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2PLoS Pathogens, 2020
- ABO Blood Group and Risk of Thromboembolic and Arterial DiseaseCirculation, 2016
- Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodiesGlycobiology, 2008